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https://doi.org/10.1016/j.stemcr.2017.09.009SUMMARYHuman endothelial colony-forming cells (ECFCs) represent a promising source of adult stem cells for vascular repair, yet their regener-
ative capacity is limited. Here, we set out to understand themolecularmechanism restricting the repair function of ECFCs.We found that
key pro-angiogenic pathways are repressed in ECFCs due to the presence of bivalent (H3K27me3/H3K4me3) epigenetic marks, which
decreases the cells’ regenerative potential. Importantly, ex vivo treatment with a combination of epigenetic drugs that resolves bivalent
marks toward the transcriptionally active H3K4me3 state leads to the simultaneous activation ofmultiple pro-angiogenic signaling path-
ways (VEGFR, CXCR4, WNT, NOTCH, SHH). This in turn results in improved capacity of ECFCs to form capillary-like networks in vitro
and in vivo. Furthermore, restoration of perfusion is accelerated upon transplantation of drug-treated ECFCs in a model of hindlimb
ischemia. Thus, ex vivo treatment with epigenetic drugs increases the vascular repair properties of ECFCs through transient activation
of pro-angiogenic signaling pathways.INTRODUCTION
Human endothelial colony-forming cells (ECFCs) are endo-
thelial progenitors that can be isolated from umbilical cord
blood and peripheral blood (Ingram et al., 2004; Lin et al.,
2000; Medina et al., 2010) or derived from induced plurip-
otent stem cells (iPSCs) (Prasain et al., 2014). These highly
proliferative cells possess the unique property of forming
functional blood vessels in vivo upon transplantation (Au
et al., 2008; Melero-Martin et al., 2007; Reinisch et al.,
2009; Yoder et al., 2007). This property distinguishes ECFCs
frommoremature endothelial cells andmakes thempartic-
ularly attractive as a cell therapy for enhanced vascular
repair in ischemic diseases such as peripheral arterial dis-
ease, ischemic retinopathy,myocardial infarction, or stroke
(Cooke and Losordo, 2015; Fadini et al., 2012; Fraineau
et al., 2015; Park and Gerecht, 2014; Shantsila et al.,
2007). Upon transplantation at sites of ischemic injury,
ECFCs incorporate into damaged blood vessels and release
pro-angiogenic growth factors to facilitate the repair pro-
cess, ultimately improving blood perfusion and organ
function (Alphonse et al., 2014; Bouvard et al., 2010; Palii
et al., 2014; Saif et al., 2010; Schwarz et al., 2012). Further-
more, ECFCs can be used to provide trophic support to
other therapeutically relevant cells (Lin et al., 2014). WhileStem Cell Report
This is an open access article under the CECFCs represent promising candidates for cell therapy, it is
critical to improve their efficacy in vivo through promoting
cell survival and increasing the kinetics of cell migration,
homing, differentiation, and secretion of pro-angiogenic
factors (Chavakis et al., 2008; Cooke and Losordo, 2015).
Studies in endothelial cells have identified several signal
transduction pathways (e.g., CXCR4, VEGF, NOTCH,
SHH, and WNT) that coordinate survival, differentiation,
arterial/venous specification, andblood-vesselmorphogen-
esis (Carmeliet and Jain, 2011; Herbert and Stainier, 2011;
Le Bras et al., 2010). Therefore, a major question is how to
activate pro-angiogenic signaling pathways in ECFCs such
that we can boost the regenerative function of these cells
and increase their survival in vivo post transplantation.
Promising results have been obtained through pre-activa-
tion of the NOTCH pathway where it was shown that the
vascular repair potential of transplanted murine endothe-
lial progenitors is significantly increased if the cells are
cultured ex vivowith stromal cells overexpressing theNotch
ligand Jag-1 prior to transplantation (Kwon et al., 2008).
Furthermore, it was recently found that co-implantation
of stromal cells expressing the Notch ligand Dll1 decreases
apoptosis and enhances the post-natal vasculogenic capac-
ity of human ECFCs in murine subcutaneous implants
(Kim et al., 2015). While activation of the Notch pathways j Vol. 9 j 1573–1587 j November 14, 2017 j ª 2017 The Authors. 1573
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Figure 1. Pharmacologic Treatment with a Combination of EZH2 and HDAC Inhibitors Enhances ECFC Migration, Capillary Network
Formation, and Resistance to Serum Starvation-Induced Apoptosis
(A) GSK-343 and panobinostat lead to a global decrease in H3K27me2/3 levels and an increase in H3/H4-acetyl levels, respectively, as
analyzed by western blot. Molecular masses are indicated in kDa. Total histone H3 and H4 serve as loading controls.
(B) GSK-343 and panobinostat do not affect the overall level of indicated proteins, as analyzed by western blot. Molecular masses are
indicated in kDa. Tubulin serves as a loading control.
(C) GSK-343 and panobinostat increase the kinetics of ECFC migration as measured by gap closure assay. Left: representative pictures of
ECFCs stained with crystal violet after 10 hr migration (103magnification; scale bar, 250 mm). Dashed circles represent the gap area prior
(legend continued on next page)
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through external stimulation of Notch receptors may
provide a valuable strategy to enhance vascular repair prop-
erties of endothelial progenitors, several other signaling
pathways (e.g., VEGFR, CXCR4, SHH,WNT) are also essen-
tial for angiogenesis and post-natal vasculogenesis. Howev-
er, an approach that simultaneously activates multiple
pro-angiogenic pathways in ECFCs is currently lacking.
We previously demonstrated that ex vivo treatment with
the histone deacetylase (HDAC) inhibitor trichostatin
A (TSA) increases ECFC-mediated vascular repair in hin-
dlimb ischemia (Palii et al., 2014), providing proof of princi-
ple that the priming of ECFCswith epigenetic drugs prior to
transplantation is a valuable strategy to improve their regen-
erative function (Fraineau et al., 2015). Stem andprogenitor
cells are characterized by a high prevalence of transcription-
ally competent but repressed (i.e., ‘‘poised’’) genes that are
marked by both active (histone H3 lysine 4 trimethylation
[H3K4me3]) and repressive (histone H3 lysine 27 trimethy-
lation [H3K27me3]) histonemodifications that play impor-
tant roles in differentiation and development (Benyoucef
and Brand, 2015; Voigt et al., 2013). While those bivalent
genes are expressed at extremely low levels, it has been pro-
posed that the presence of H3K4me3 may prime them for
rapid activation upon removal of H3K27me3. Here, we set
out to test the hypothesis that decreasing the levels of the
repressive mark H3K27me3 with epigenetic drugs could
improve thevascular repair properties of ECFC throughacti-
vation of pro-angiogenic signaling pathways.RESULTS
A Combination of Epigenetic Drugs Increases ECFC
Migration, Capillary Network Formation, and
Resistance to Serum Starvation-Induced Apoptosis
Repressive histone marks H3K27me2/3 are established on
chromatin by the polycomb group repressive complex 2to cell migration. Right: fraction of the gap area invaded by migra
experiments (n = 3) each performed in duplicate are shown ±SEM.
(D) GSK-343 and panobinostat increase ECFC-mediated capillary-like
capillary-like structures stained with calcein (2.53 magnification; sc
pressed as the mean percentage of control values corresponding to ce
experiments (n = 3) each performed in duplicate.
(E) GSK-343 and panobinostat do not induce apoptosis in ECFCs as mea
annexin V staining.
(F) GSK-343 and panobinostat reduce serum starvation-induced apo
staining. ECFCs were grown in serum-containing EGM-2 medium or se
(E and F) Data expressed as mean percentage of control values corres
experiments (n = 3), each performed in duplicate.
(G) GSK-343 and panobinostat decrease ECFC proliferation as analyzed
incorporating BrdU is indicated ±SEM from four independent experim
***p < 0.001; **p < 0.01; *p < 0.05; ns, non-significant. See also Fi(PRC2), a protein complex comprised of three core sub-
units: methyltransferase EZH2 and two other proteins,
EED and SUZ12, both of which are required for PRC2 cat-
alytic activity (Di Croce and Helin, 2013). To decrease
H3K27me2/3 levels, we treated human umbilical cord
blood-derived ECFCs with GSK-343, a potent and selective
inhibitor of EZH2 (Verma et al., 2012). As expected, GSK-
343 exposure led to a global decrease of H3K27me2/3
levels in a time- and dose-dependent manner (Figures
1A, S1A, and S1B). Importantly, other histone marks,
such as H3K27me1, H3K4me3, H3K9me3, H4K20me3,
or histone acetylation, are not affected (Figures 1A and
S1B). Furthermore, GSK-343 does not lead to a decrease
of PRC2 subunits nor does it alter the level of other chro-
matin-modifying enzymes, including the acetyltransfer-
ase P300, the deacetylase HDAC1, the H3K27 demethy-
lase UTX, the H3K9 methyltransferase G9a, or the DNA
methyltransferases DNMT1 and DNMT3A (Figure 1B).
This is in contrast to the widely used S-adenosylhomocys-
teine hydrolase inhibitor 3-deazaneplanocin (DZNep),
which depletes PRC2 subunits and leads to a global
decrease of multiple histone marks, including
H3K27me2/3 but also H4K20me3, H3K9me3, H3K4me3,
and others (Helin and Dhanak, 2013; Miranda et al.,
2009; Ohtani et al., 2011; Tan et al., 2007). Thus, in
contrast to DZNep, GSK-343 is a potent and selective in-
hibitor of EZH2 in ECFCs.
Next, we examined the effects of GSK-343 on the capac-
ity of ECFCs to migrate (using a gap closure assay) and to
form a capillary-like network on Matrigel. These experi-
ments revealed that GSK-343 significantly improves the
pro-angiogenic properties of ECFCs, increasing both the
kinetics of cell migration (Figure S1C) and the capacity of
ECFCs to form a capillary-like network (Figure S1D) in a
dose-dependent manner. Consistent with this, we found
that knocking down EZH2 also increases ECFC-mediated
capillary network formation (data not shown). Thus,ting cells at the indicated times. Average from thee independent
structure formation on Matrigel. Left: representative pictures of
ale bar, 1 mm). Right: total capillary length of the network is ex-
lls treated with vehicle ±SEM. Data shown from three independent
sured by fluorescence-activated cell sorting (FACS) after 7-AAD and
ptosis in ECFCs as measured by FACS after 7-AAD and annexin V
rum-depleted EBM-2 medium.
ponding to cells treated with vehicle ±SEM from three independent
by bromodeoxyuridine (BrdU) incorporation. The percentage of cells
ents (n = 4), each performed in duplicate.
gures S1 and S2.
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Figure 2. Pharmacologic Treatment of ECFCs with a Combination of EZH2 and HDAC Inhibitors Activates Multiple Pro-angiogenic
Pathways Simultaneously
(A) Global changes in gene expression upon drug treatment versus vehicle treatment analyzed by RNA-seq. Scatterplot shows upregulated
(red) and downregulated (green) genes (n = 3).
(B) Representative Gene Ontology (GO) Biological Process categories significantly enriched for up- and downregulated genes in ECFCs
treated with GSK-343 and panobinostat.
(C) Heatmaps of up- and downregulated genes that belong to the indicated signaling pathways as identified by RNA-seq analysis and
validated by qRT-PCR (*). Data are expressed in log2(FPKM) (n = 3). The feedback arrow indicates a gene belonging to both receptor and
target gene categories.
(legend continued on next page)
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inhibition of EZH2 is an efficient strategy to improve the
angiogenic properties of ECFCs in vitro.
We showed previously that pre-treatment with the
histone deacetylase (HDAC) inhibitor TSA increases
ECFC-mediated capillary network formation (Palii et al.,
2014). Since GSK-343 has no effect on histone acetyla-
tion (Figures 1A and S1B), we hypothesized that
combining EZH2 and HDAC inhibitors may further
improve ECFC function by acting on complementary
epigenetic pathways. To test this hypothesis, we sought
to use the highly potent class I, II, and IV HDAC inhibi-
tor panobinostat (LBH589), which is less toxic than
TSA and is already clinically approved for cancer treat-
ment (Andreu-Vieyra and Berenson, 2014; Dokmanovic
et al., 2007). First, we confirmed that panobinostat
used as a single agent is at least as efficient as TSA
for improving the pro-angiogenic capacity of ECFCs,
increasing both cell migration (Figure S2D) and capil-
lary network formation (Figure S2E). Furthermore, we
confirmed that, at the established optimal conditions
(i.e., 10 nM for 2 hr), panobinostat leads to a significant
increase in the global levels of histone H3 and H4 acety-
lation without affecting H3K27me3 or other histone
modifications (Figures S2A–S2C and 1A). Having estab-
lished optimal conditions for GSK-343 and panobinostat
treatments as single agents, we combined these epige-
netic drugs to determine whether we could further
improve the pro-angiogenic functions of ECFCs. These
experiments show that a combined treatment consisting
of 72 hr incubation with the EZH2 inhibitor GSK-343 at
5 mM and 2 hr incubation with the HDAC inhibitor pan-
obinostat at 10 nM is significantly more efficient at
increasing the migration kinetics of ECFCs (Figure 1C)
and capillary network formation (Figure 1D) than either
drug alone. Furthermore, the combined treatment is spe-
cific to H3K27 di- and tri-methylation and to H3- and
H4-acetylation without affecting other histone marks
(Figure 1A) and without altering the levels of the en-
zymes responsible for H3K27 methylation/demethyla-
tion and H3/H4 acetylation/deacetylation (Figure 1B).
We also verified that the drug combination does not
induce apoptosis as measured by annexin V staining
(Figure 1E). Rather, we found that treatment with
GSK-343 and panobinostat increases the resistance of
ECFCs to serum starvation-induced apoptosis (Figure 1F).
Finally, we noted a slight decrease in ECFC proliferation(D) Validation of cell-signaling pathway activation upon drug treatm
shows an increase in global protein levels of VEGFR1 (FLT1), VEGFR2 (
CXCR4 upon drug treatment. Middle: western blot analysis of VEGFR2 im
drug treatment. Right: western blot analysis of ECFC extracts shows an
Tubulin is used as a loading control. Molecular masses are indicated
See also Figures S3 and S4 as well as Tables S1 and S2.upon drug treatment (Figure 1G). Thus, a combined
treatment using an EZH2 inhibitor followed by an
HDAC inhibitor is an efficient strategy to enhance the
pro-angiogenic properties of ECFCs and increase their
resistance to apoptosis.
Combined Treatment of ECFCs with Epigenetic Drugs
Activates Multiple Pro-angiogenic Pathways
Simultaneously
To better understand the mechanism through which the
combined treatment of GSK-343 and panobinostat
increases the pro-angiogenic properties of ECFCs, we
measured changes in gene expression by RNA sequencing
(RNA-seq) immediately upon drug treatment (i.e., 72 hr
incubation with the EZH2 inhibitor GSK-343 at 5 mM
followed by 2 hr incubation with the HDAC inhibitor
panobinostat at 10 nM). This experiment, performed
using two independently generated ECFC clones from
two distinct cord blood donors, identified 553 upregu-
lated genes and 329 downregulated genes (p < 0.05)
(Figure 2A). RNA-seq results were confirmed by qRT-PCR
for all genes tested (Figures 3A, S4, S5A, and data not
shown). Gene ontology (GO) analysis indicates that upre-
gulated genes are enriched in categories related to blood-
vessel development, cell motion, cell adhesion, and
response to wounding (Figures 2B and S3A), which con-
firms that the epigenetic drug combination increases the
pro-angiogenic properties of ECFCs. In contrast, downre-
gulated genes are enriched in categories related to cell
division and proliferation, consistent with the slight
decrease in cell proliferation observed upon drug treat-
ment (Figure 1G). See Tables S1 and S2 for a complete
list of changing genes and GO categories. Most interest-
ingly, a pathway analysis identified NOTCH and WNT
(wingless-type mouse mammary tumor virus integration
site) transduction pathways as being significantly en-
riched for activated genes (Figure S3B). Furthermore, we
noticed that three additional pro-angiogenic pathways,
CXCR4 (for C-X-C chemokine receptor type 4), VEGFR
(for vascular endothelial growth factor receptor), and
SHH (for sonic hedgehog), are also activated upon drug
treatment (Figure 2C). All five transduction pathways acti-
vated by the epigenetic drug combination have previously
demonstrated pro-angiogenic roles, with VEGFR being a
master regulator of all aspects of angiogenesis and vascu-
logenesis (including cell survival, proliferation, migration,ent at the protein level. Left: western blot analysis of ECFC extracts
KDR), cleaved intracellular domain of NOTCH1 (NOTCH1-NICD), and
munoprecipitates (IP) shows an increase in phospho-VEGFR2 upon
increase in phospho-AKT and phospho-ERK1/2 upon drug treatment.
in kDa.
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Figure 3. Pharmacologic Treatment of ECFCs with a Combination of EZH2 and HDAC Inhibitors Increases Gene Expression through
H3K27me3 Demethylation and Histone H3 Acetylation
(A) Transcript levels of indicated genes were measured by qRT-PCR following treatment of ECFCs with vehicle, GSK-343, panobinostat, or
GSK-343-panobinostat combination, as indicated. qRT-PCR values are expressed as mean percentages of vehicle-treated cells ±SEM with
B2M serving as internal control. (nR 3). ***p < 0.001; *p < 0.05; ns, non-significant.
(B) RNA polymerase II (pol II) binding to indicated gene promoters was assessed by ChIP-qPCR.
(C–E) Enrichment of H3K27me3 (C), H3K4me3 (D), and H3 acetyl (E) histone marks to indicated gene promoters was assessed by
ChIP-qPCR.
(B–E) ChIPs were performed using indicated antibodies (Ab) or IgG as a negative control (Mock). qPCR values are expressed as mean
fractions of input ±SD.
See also Figure S5.
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differentiation, and morphogenesis), CXCR4 promoting
endothelial progenitor cell migration, and homing, while
NOTCH, WNT, and SHH pathways play critical roles in
regulating vessel formation, branching, and maturation
(Carmeliet and Jain, 2011; Chavakis et al., 2008; Dejana,
2010; Herbert and Stainier, 2011; Le Bras et al., 2010;
Park et al., 2013). Interestingly, for each signaling
pathway, upregulated genes belong to ligands, receptors,
and downstream target genes (Figure 2C), which indicates
global activation upon drug treatment. For instance,
ligands (DKK3, WNT5A, WNT9A, WNT4, and WNT11),
receptors (FZD2, FZD1, FZD5, and FZD7), and target
genes (TCF7L1, JAG1, MML1, and EGR1) of the WNT
pathway are activated (Figure 2C and see Figures S3D
and S4 for selected examples). Furthermore, negative reg-
ulators of WNT and VEGFR pathways (e.g., DKK1 as well
as SEMA3A) are downregulated (Figure 2C). Noticeably,
parsing the genes in categories according to their expres-
sion levels reveals that the drug combination activates
low-to-moderately expressed genes (e.g., CXCL12, FZD7,
DLL1, SHH, CXCR4, DLL4), whereas genes that are already
expressed at high levels (e.g., the transcription elongation
factor gene ELP3 or the endothelial nitric oxide synthase
[eNOS] gene NOS3; Chan et al., 2004) are not significantly
affected (Figure S3C). Finally, we confirmed activation of
the identified pro-angiogenic pathways at the protein
level by western blot where we detected increased levels
of VEGFR1, VEGFR2, intracellular NOTCH, and CXCR4,
as well as increased phosphorylation of VEGFR2, AKT,
and ERK1/2 proteins (Figure 2D). Taken together, these re-
sults indicate that in ECFCs, pro-angiogenic pathways are
maintained in a repressed/poised state. Most importantly,
we found that five major pro-angiogenic transduction
pathways can be activated in ECFCs through the com-
bined action of the epigenetic drugs GSK-343 and panobi-
nostat. Thus, multiple pro-angiogenic signaling pathways
can be activated simultaneously in endothelial progeni-
tors through ex vivo drug treatment.
Activation of Pro-angiogenic Pathways by Epigenetic
Drugs Occurs through Resolving Bivalently Marked
Genes
To better understand the mechanism of action of panobi-
nostat andGSK-343, we further dissected the effect of these
drugs (alone and in combination) on genes representative
of various pathways. Interestingly, even though all genes
tested are significantly increased upon treatment with the
drug combination (validating our RNA-seq results), some
genes respond to both drugs in a seemingly additive
fashion (e.g., FZD7, KDR,DLL4,HEY2) while others appear
to be more responsive to the HDAC inhibitor (e.g., DLL1,
SHH) or to the EZH2 inhibitor (e.g., CXCR4, CXCL12,
ANGPT2) with ELP3 serving as a control not altered bydrug treatment (Figures 3A and S4). These differential
effects on gene expression are reflected by differential
RNA polymerase II (pol II) binding on gene promoters
(Figure 3B). Then, we examined the effects of the drugs
(alone and in combination) on histone post-translational
modifications (PTMs). Consistent with their highly specific
effects on global histone PTMs levels (Figures 1A, S1B, and
S2C), we found that both drugs modify their respective
targets without affecting other histone PTMs. Specifically,
the EZH2 inhibitor GSK-343 decreases the repressive
histone mark H3K27me3 on all three representative genes
(Figure 3C) with no effect on H3K4me3 (Figure 3D) or
H3-Ac (Figure 3E). Similarly, the HDAC inhibitor panobi-
nostat increases histone H3 acetylation on all genes tested
(Figure 3E) with no effect on H3K27me3 (Figure 3C) or
H3K4me3 (Figure 3D). Taken together, these results indi-
cate that the combination of GSK-343 and panobinostat
increases gene expression in ECFCs through a mechanism
that entails removal of the repressive histone mark
H3K27me3 and increase in the active histone mark H3-Ac.
Interestingly, these experiments also revealed several
properties of the genes that respond to the drug combina-
tion, including (1) the presence of both active (H3K4me3
and H3-Ac) and repressive (H3K27me3) histone marks on
their promoter (Figures 3C, 3D, and 3E); (2) low, but detect-
able pol II binding on their promoter (Figure 3B); and (3) a
low level of expression (Figure S3C). These properties char-
acterize a particular sort of genes named ‘‘bivalent’’ that are
maintained in a state of equilibrium between full repres-
sion and full activation (Benyoucef and Brand, 2015; Voigt
et al., 2013). Even though bivalent genes are found in
differentiated cells, they are more prevalent in stem/pro-
genitor cells (e.g., Cui et al., 2009; Karmodiya et al., 2012;
Mikkelsen et al., 2007), and they are poised to respond
quickly (positively or negatively) to signaling cues from
the environment (Benyoucef and Brand, 2015; Voigt
et al., 2013). Bivalent genes differ both from highly ex-
pressed genes (e.g., ELP3 and NOS3) that are devoid of the
repressive mark H3K27me3 (Figures 3 and S5) and from
completely repressed genes (e.g., the non-endothelial
genes PAX7 andMYOD) that are devoid of the active marks
H3K4me3 and H3-Ac and do not display pol II binding
(Figure S5).
To better understand the mechanism leading to
H3K27me3 removal and H3-Ac increase upon drug treat-
ment, we tested for binding of the epigenetic enzymes
responsible for adding/removing these histone modi-
fications. Interestingly, we found that bivalent gene
promoters are co-bound by enzymes with antagonistic ac-
tivities: (1) the H3K27 methyltransferase EZH2 and the
H3K27 demethylase UTX, as well as (2) the histone acetyl-
transferase P300 and the histone deacetylase HDAC1 (Fig-
ure 4). Furthermore, these enzymes remain tethered to theStem Cell Reports j Vol. 9 j 1573–1587 j November 14, 2017 1579




(A–D) Binding of the H3K27 methyl-
transferase EZH2 (A), the H3K27 demethy-
lase UTX (B), the histone deacetylase
HDAC1 (C), and the histone acetyltransfer-
ase p300 (D) to indicated gene promoters
was measured by ChIP-qPCR. ChIPs were
performed using indicated antibodies (Ab)
or IgG as a negative control (Mock). qPCR
values are expressed as mean fractions of
input ±SD.
(E) Model representing co-binding of
antagonistic enzymes on gene promoters
such that transcription is maintained at low
levels (poised gene). Combined inhibition
of the repressive enzymes EZH2 and HDAC1
displaces the equilibrium leading to tran-
scriptional activation.genes upon drug treatment (data not shown). In contrast,
EZH2 is not bound to the promoter of the highly ex-
pressed ELP3 gene (Figure 4A), consistent with the
absence of H3K27me3 at this site (Figure 3C). Taken
together, these results suggest that in non-treated ECFCs,
EZH2 and UTX compete for methylation/demethylation
of H3K27 at bivalent gene promoters, resulting in an
enrichment of the repressive histone mark H3K27me3
(Figure 3C) that is sufficient to maintain low levels of
gene expression (i.e., poised status) (Figures 3A, 4E, S3C,
S3D, and S4). When EZH2 is inhibited (upon GSK-343
treatment), the equilibrium is displaced in favor of UTX,
which rapidly removes the repressive mark H3K27me3
(Figure 3C), leading to increased gene transcription (Fig-
ures 3A, 4E, S3C, and S3D). A similar mechanism appears
to be in place for histone acetylation/deacetylation where
P300 and HDAC1 are co-bound to bivalent gene pro-
moters (Figure 4) and compete for histone modification,
resulting in increased acetylation upon panobinostat-
mediated inhibition of HDAC activity (Figure 3E). Thus,
ECFCs maintain specific genes in a repressed/poised state
through the recruitment of antagonistic ‘‘activating’’ and1580 Stem Cell Reports j Vol. 9 j 1573–1587 j November 14, 2017‘‘repressive’’ chromatin-modifying enzymes that establish
a bivalent gene promoter status characterized by the pres-
ence of both active (H3K4me3 and H3-Ac) and repressive
(H3K27me3) histone marks (Figure 4E). Importantly, this
poised/bivalent status can be resolved through pharmaco-
logic inhibition of the repressive enzymes EZH2 and
HDAC leading to full gene activation.
Gene Activation Mediated by HDAC and EZH2
Inhibitors Is a Reversible Process
Co-binding of antagonistic chromatin-modifying enzymes
on bivalent gene promoters (Figure 4) predicts that gene
activation through pharmacologic inhibition of HDACs
and EZH2 will be reversible upon drug removal. To test
this hypothesis, ECFCs were treated with a combination
of GSK-343 and panobinostat. Then, treated ECFCs were
harvested, washed, and re-plated in the absence of the
epigenetic drug cocktail. Measuring gene expression and
histone PTMs at several time points after re-plating,
we observed both increased H3K27me3 and decreased
H3-Ac at promoters of pro-angiogenic genes upon drug
removal (Figures 5B and 5C). Furthermore, after 24 hr,
Figure 5. Gene Activation upon Treatment with a Combination of HDAC and EZH2 Inhibitors Is Reversible
(A) Transcript levels of indicated genes were measured by qRT-PCR at the indicated times after removal of the GSK-343/panobinostat drug
combination. qRT-PCR values are expressed as mean percentages of vehicle-treated cells ±SEM with B2M serving as internal
control. (n = 3).
(B and C) Enrichment of H3K27me3 (B) and H3 acetyl (C) histone marks is measured by ChIP-qPCR at the indicated times after removal of
the GSK-343/panobinostat drug combination. qPCR values are expressed as mean fractions of input ±SD.
***p < 0.001; **p < 0.01; *p < 0.05; ns, non-significant.the pro-angiogenic genes had reverted back to their native
transcriptionally repressed status (Figure 5A). Taken
together, these results confirm the transient nature of pan-
obinostat-/GSK-343-mediated epigenetic modifications at
pro-angiogenic genes in ECFCs.
Pharmacologic Inhibition of HDAC and EZH2
Increases ECFC-Mediated Vasculogenesis and
Improves the Therapeutic Potential of Transplanted
ECFCs in a Hindlimb Ischemia Mouse Model
The results described above revealed that several major pro-
angiogenic transduction pathways are activated in ECFCs
through pharmacologic inhibition of EZH2 and HDACs.
To determine whether these effects translate into increased
vasculogenesis in vivo, ECFCs were pretreated with GSK-
343 and panobinostat prior to embedding into collagen
matrices that were subcutaneously implanted into im-
munodeficient mice (Prasain et al., 2012). After 3 weeks,implants were harvested and analyzed for blood-vessel
formation using a human-specific CD31 antibody as previ-
ously described (Prasain et al., 2012). This experiment
revealed the formation of ECFC-derived micro-capillaries
(Figure 6A) where the presence of surrounding murine
smooth muscle cells suggests capillary maturation (Fig-
ure S6). Furthermore, the number of these human, ECFC-
derived capillaries is significantly increased in implants
from drug-treated ECFCs (Figure 6A, right panel), confirm-
ing the efficacy of combined GSK-343 and panobinostat
treatment in improving ECFC-derived vasculogenesis
in vivo.
Finally, we sought to determine the extent to which
ex vivo treatment with epigenetic drugs enhances the
vascular repair function of ECFCs. To address this ques-
tion, we used a murine model of hindlimb ischemia (Lim-
bourg et al., 2009; Palii et al., 2014), where ischemia is
induced by ligation of the left femoral artery, followedStem Cell Reports j Vol. 9 j 1573–1587 j November 14, 2017 1581
Figure 6. Pharmacologic Treatment with a Combination of EZH2 and HDAC Inhibitors Accelerates Vasculogenesis and Blood-Flow
Recovery by Transplanted ECFCs in a Mouse Model of Hindlimb Ischemia
(A) H&E staining (left) and anti-human (h) CD31 staining (right) identify ECFCs that have formed micro-capillaries in collagen gels after
3 weeks of implantation in mice (scale bar, 200 mm). Numbers of fully closed ECFC-derived hCD31+ capillaries are indicated per measured
explanted area as mean values ± SEM (n = 6 mice per group).
(B) Laser Doppler perfusion imaging was used to measure blood flow pre-operatively (pre-op), immediately after induction of hindlimb
ischemia (day 0) and at the indicated time points after injection of ECFCs pretreated with vehicle or with the drug combination. Left:
representative laser Doppler images (Isch., Ischemic leg; NI, non-ischemic leg). Right: perfusion ratios (Isch./NI) are indicated as mean
values ± SEM (ECFCs: days 0–14, n = 7 mice; days 21–28, n = 3 mice. ECFCs treated: days 0–14, n = 8 mice; days 21–28, n = 4 mice).
(legend continued on next page)
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by intramuscular injection of treated or non-treated
ECFCs as cell therapy. This experiment revealed that
ECFCs pretreated ex vivo with GSK-343 and panobinostat
are more rapid at restoring blood flow in the ischemic leg
compared with their non-treated counterparts (Figure 6B).
Specifically, by measuring blood flow using Doppler
analysis at several time points after cell therapy, we found
that the kinetics of blood-flow recovery in the ischemic
leg is significantly accelerated when GSK-343-panobino-
stat-treated ECFCs are used for transplantation (Figure 6B).
This improvement is therapeutically relevant given that
the speed of blood-flow recovery is one of the most
important factors in saving organ function after acute
ischemia (Callum and Bradbury, 2000; Creager et al.,
2012). Furthermore, the improved perfusion persists for
at least 4 weeks post transplantation in mice injected
with either drug-treated or non-treated ECFCs (Figure 6B).
Thus, pre-activation of ECFCs with a cocktail of epigenetic
drugs (i.e., EZH2 and HDAC inhibitors) administered
ex vivo is a promising strategy to increase the therapeutic
potential of these cells and boost their vascular repair
function in vivo through increased activity of multiple
pro-angiogenic signaling pathways (Figure 6C).DISCUSSION
ECFCs are human endothelial progenitor cells with unique
capabilities to form vascular structures in several animal
models of ischemia (Palii et al., 2014; Prasain et al.,
2014). However, these cells have not been fully character-
ized and additional strategies are needed to improve their
therapeutic potential. Here, we show that ECFCs maintain
several key pro-angiogenic pathways (i.e., NOTCH, WNT,
CXCR4, VEGFR, and SHH) in a repressed/poised state
through the establishment of bivalent gene promoters
that are characterized by the simultaneous enrichment of
active and repressive histone PTMs. This equilibrium is
maintained by epigenetic enzymes with competing activ-
ities (i.e., EZH2/UTX and P300/HDAC1) that are co-bound
to gene promoters, resulting in low expression levels.
In vivo, ECFCs presumably require external signals from
the environment to fully activate pro-angiogenic pathways
in response to vascular injury. Interestingly, our results
indicate that this activation process can be initiated
ex vivo prior to transplantation through pharmacologic ap-
proaches with specific EZH2 and HDAC inhibitors. Impor-
tantly, this ex vivo ‘‘boosting’’ procedure that leads to the(C) EZH2 and HDAC inhibitors upregulate multiple transduction pathw
Schematic representation of cell-signaling molecules and processes th
of ECFCs with the GSK-343 and panobinostat combination.
**p < 0.01; *p < 0.05. See also Figure S6.activation of multiple pro-angiogenic pathways in ECFCs
is translated in vivo by enhanced vasculogenesis, angiogen-
esis, and accelerated vascular repair in a hindlimb ischemia
model. Furthermore, the reversible nature of epigenetic
modifications ensures that the injected cells remain
responsive to signals from the environment, optimizing
vascular repair to the host’s specific needs and limiting po-
tential adverse effects such as blood-vessel overgrowth.
In this study, we have focused on histone modifications
enriched on promoters of specific genes that belong to
pro-angiogenic pathways. Future studies, using genome-
wide approaches, are necessary to identify the full extent
of bivalent promoters in ECFCs. Furthermore, bivalent
marks have also been identified on distal regulatory ele-
ments (Mikkelsen et al., 2007), suggesting that our epige-
netic drug cocktail may also affect the epigenetic state of
enhancers. A detailed understanding of enhancer/pro-
moter communications in ECFCs, as determined by chro-
mosome conformation capture (3C) approaches (Davies
et al., 2017), will be required as a pre-requisite to appreciate
the full extent of epigenetic changes occurring upon drug
treatment and their consequences on gene expression
and vascular repair.EXPERIMENTAL PROCEDURES
Cell Isolation and Culture
All procedures were approved by the Ottawa Hospital Research
Ethics Board (2007804-01H). Human ECFCs were derived from
umbilical cord blood obtained after informed consent from theCa-
nadian Cord Blood for Research Program (2014.007) and cultured
as previously described (Palii et al., 2014; Yoder et al., 2007). Briefly,
mononuclear cells were isolated by Ficoll density gradient centrifu-
gation and seeded onto CellBIND sux-well plates (Corning) at a
density of 107 mononuclear cells/well in EGM-2 BulletKit medium
(Lonza) supplemented with 10% fetal bovine serum. Individual
ECFC colonies were re-plated separately and analyzed by flow
cytometry (CD31+/CD34+/CD45) after each passage. All experi-
ments were performedwith at least three biologically independent
ECFC clones between passage 3 and 6.Capillary-like Network Formation Assay
ECFCs, pretreated with epigenetic drugs or vehicle as indicated,
were seeded into 96-well plates previously coated with 50 mL of
phenol-red-free, growth factor reduced Matrigel (Corning) at a
density of 5,000 cells/well in duplicates. After 24 hr, cells were
stained with 5 mg/mL calcein (BD Bioscience) for 5 min at 37C
and photographed using an Axiovert S100 microscope (Zeiss)ays in ECFCs.
at are upregulated (red) or downregulated (green) upon treatment
Stem Cell Reports j Vol. 9 j 1573–1587 j November 14, 2017 1583
and AxioVision 4.6 software at 2.53 magnification. Total tube
length was quantified using AngioQuant software as described
(Fraineau et al., 2012).
Cell Migration Assay by Gap Closure
ECFC migration was measured by gap closure assay using the
Radius 96-well cell migration assay (Cell Biolabs) according to the
manufacturer’s instructions. Briefly, 2 3 104 ECFCs, pretreated
with epigenetic drugs or vehicle, were seeded into a 96-well plate
containing a hydrogel plug and allowed to adhere onto the plate.
The plugwas removed providing a cell-free area, and cellmigration
into the gap was monitored by taking pictures every 3 hr using an
Axio Observer.A1 microscope (Zeiss) and AxioVision 4.6 software
at 103magnification. Once confluent, cells were labeledwith crys-
tal violet (Cell Biolabs). The cell-free area was measured using
MATLAB software,whichprovides a simple graphical user interface
throughwhich a user can select an image to calculate the area auto-
matically or manually. Automatic segmentation begins with gray-
level thresholding of the input image, then SD filtering on the
thresholded image, followed by a series of morphological opera-
tions to detect the cell-free area and calculate the area size in pixels.
Serum Starvation and Apoptosis Assay by Annexin
V Staining
ECFCs were plated into 6-well plates containing EBM-2 medium
without addition of EGM-2 SingleQuots (Lonza) and incubated
overnight (16 hr) prior to harvesting and suspension in annexin
V binding buffer (BD Pharmingen). Apoptosis was then assessed
using the Annexin V PE Apoptosis Detection Kit I (BD Pharmin-
gen) according to the manufacturer’s instructions.
ECFC Transplant in NOD/SCID Mice
Three-dimensional cellularized collagen matrices were prepared as
previously described using the Standardized Oligomer Polymeriza-
tion Kit (GeniPhys, Indiana, USA) (Prasain et al., 2014). Briefly,
type I collagen gels (1.5 mg/mL) were prepared on ice, mixed
immediately with ECFCs (4 3 106 cells/mL) that had been treated
(or not) with the epigenetic drug cocktail as indicated, and left to
polymerize for 30min at 37C in a CO2 incubator prior to the addi-
tion of 500 mL of culture medium in the absence of GSK-343 and
panobinostat. After 18 hr incubation, cellularized gels were im-
planted into the flanks of 6- to 12-week-old NOD/SCID mice, as
described (Prasain et al., 2012). Surgical procedures were conduct-
ed under anesthesia and a constant supply of oxygen. Three weeks
after implantation, gels were recovered fromanimals that had been
humanely euthanized per approved IACUC protocol.
Histology was performed using H&E stain and immunohisto-
chemistry using an anti-human CD31 antibody. Briefly, gel ex-
plants were formalin fixed, processed, and embedded in paraffin,
followed by serial sectioning (4 mm) using a Leica microtome.
Paraffin-embedded tissue sections were deparaffinized in xylene
and rehydrated through a 100%–70% ethanol gradient. Heat-
induced epitope retrieval was performed at 110C, 12 min with
EDTA buffer (pH 9.0), and 3%H2O2 was used to block endogenous
peroxidases. Sections were blocked with Background Sniper re-
agent (BioCare Medical, CA, USA) and incubated with mouse
anti-hCD31 Ab (DAKO, clone JC70A) for 1 hr at room temperature1584 Stem Cell Reports j Vol. 9 j 1573–1587 j November 14, 2017(1:2,000 dilution). The MACH4+ DAB detection system was used
according to the manufacturer’s instructions (BioCare Medical,
CA, USA). ECFC-derived hCD31+ blood vessels were imaged using
an Aperio ScanScope XT (Leica Microsystems).
Mouse Model of Hindlimb Ischemia
ECFC-induced vascular repair was assessed using a hindlimb
ischemia mouse model as described (Kuraitis et al., 2011; Palii
et al., 2014). All procedures were approved by the University of
Ottawa Animal Care Committee and performed in accordance
with the National Institute of Health Guide for the Care and Use
of Laboratory Animals. Ischemia was induced in the left hindlimb
of 8-week-old athymic nude CD1 female mice by ligation of the
proximal end of the femoral artery. ECFCs were injected immedi-
ately after skin closure. Specifically, 5 3 105 ECFCs, pretreated
with the drug combination or vehicle as indicated, were re-sus-
pended in 50 mL of PBS and delivered by two equivolumetric injec-
tions into the adductor muscle, downstream of the unilateral left
hindlimb ligation site, using an insulin syringe. Blood perfusion
was monitored pre-operatively, immediately after surgery, and at
the indicated days post operation by laser Doppler perfusion imag-
ing (moorLDI2; Moor Instruments). Results are expressed as the
ratio of ischemic to non-ischemic hindlimb perfusion. For non-
treated ECFCs, seven mice were monitored up to 14 days, three
of which were maintained for up to 4 weeks to evaluate the persis-
tence of blood perfusion. For drug-treated ECFCs, eight mice were
monitored up to 14 days, four of which were maintained for up to
4 weeks to evaluate the persistence of blood perfusion.
RNA Extraction, Gene Expression Profiling by RNA
Sequencing, and Bioinformatics Analysis
For RNA-seq, we used two independent ECFC clones (clone A and
clone B) at passage 3 originating from two distinct cord blood sam-
ples, as well as clone A at passage 4 (i.e., clone A0). Clones A, A0, and
B were treated with epigenetic drugs or vehicle independently of
each other, and therefore represent three biological replicates.
For each clone, total RNA was extracted from 106 ECFCs using
the RNeasy Mini Kit (QIAGEN), including a genomic DNA
digestion step with DNase I (QIAGEN), and analyzed by high-
throughput sequencing as previously described (Benyoucef et al.,
2016).
Chromatin Immunoprecipitation
Analysis of histone modifications was performed by native
chromatin immunoprecipitation (ChIP) as described (Brand
et al., 2008). Cofactor binding was assessed by crosslink ChIP as
described (Palii et al., 2014). ChIPed DNA was purified by
phenol-chloroform extraction, precipitated with ethanol, and
specific DNA sequences were amplified with PerfeC TaSYBRGreen
SuperMix (Quanta Biosciences) using a Rotor-Gene Q real-time
PCR system (QIAGEN). ChIPed DNA quantity was calculated
compared with a genomic DNA standard curve using Rotor-Gene
Q Series Software 1.7 (QIAGEN) with R2 > 0.96.
Statistical Analyses
Data obtained fromat least three independent experiments each in
duplicate or triplicate were expressed either as mean values or
percentages of control values ± SD or SEM.When indicated, statis-
tical significance between data groups was determined by non-
parametric Kruskal-Wallis test followed by Dunn’s post hoc test,
or parametric one- or two-way ANOVA followed by Dunnett or
Bonferroni post hoc test using GraphPad Prism 5 software. Use of
the non-parametric Kruskal-Wallis test or ANOVA was determined
depending on their distribution assessed by the Shapiro-Wilk
normality test. Data are considered to be significantly different at
p < 0.05. The p values are depicted with asterisks in the figures as
follows: ***p < 0.001; **p < 0.01; *p < 0.05; ns, non-significant;
ND, non-determined.ACCESSION NUMBERS
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